We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Composition of the Gut Microbiome Differentiates Normal Individuals from Those with Precancerous Polyps or Invasive Colorectal Cancer

By LabMedica International staff writers
Posted on 18 Aug 2014
Print article
A recent paper described how analysis of the gut microbiome could be used to differentiate healthy individuals from those with precancerous adenomatous polyps and those with invasive colorectal cancer.

Investigators at the University of Michigan (Ann Arbor, USA) characterized the gut microbiome in 90 patients from three clinical groups representing the stages of colorectal cancer development: healthy, adenoma, and carcinoma (30 patients representing each group). To identify the bacteria present in each individual's gut microbiome, the investigators sequenced the V4 region of the 16S rRNA gene.

They reported that analysis of the gut microbiome from stool samples revealed both an enrichment and depletion of several bacterial populations associated with adenomas and carcinomas. Combined with known clinical risk factors of colorectal cancer such as BMI (body mass index), age, and race; data from the gut microbiome significantly improved the ability to differentiate between healthy, adenoma, and carcinoma clinical groups relative to risk factors alone.

"We found that the composition of the gut microbiome allowed us to identify who in our study had precancerous adenomatous polyps and who had invasive colorectal cancer," said senior author Dr. Patrick D. Schloss, associate professor of microbiology and immunology at the University of Michigan. "If our results are confirmed in larger groups of people, adding gut microbiome analysis to other fecal tests may provide an improved, noninvasive way to screen for colorectal cancer."

"Our data show that gut microbiome analysis has the potential to be a new tool to noninvasively screen for colorectal cancer," said Dr, Schloss. "We do not think that this would ever replace other colorectal cancer screening approaches, rather we see it as complementary."

The gut microbiome study was published in the August 7, 2014, online edition of the journal Cancer Prevention Research.

Related Links:
University of Michigan

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit
New
Chemistry Analyzer
MS100

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.